News / All News / Article

Penguin Case Study | The Digital Secrets to Sustainable Growth for Pharmaceutical Companies—Highlights from Weiming Penguin Co-Founder and President Tian Ying's Presentation at the 11th Pharmaceutical and Healthcare Digital Technology Conference

Article images may contain Chinese text.

At a critical stage in the digital transformation of pharmaceuticals and healthcare, the 11th Pharmaceutical and Healthcare Digital Technology Conference became a focal point for the industry. Weiming Penguin Co-Founder and President Tian Ying delivered a keynote titled “The Digital Secrets to Sustainable Growth for Pharmaceutical Companies.” Like a stone cast into a lake, it set off waves, offering in-depth thinking and a way forward for AI-powered digital transformation in the pharmaceutical industry. During this presentation, Weiming Penguin and DingTalk's healthcare industry solutions architect jointly presented their approaches.

Drawing on deep industry insight and practical experience, Tian Ying analyzed the core logic and implementation paths of digital transformation for pharmaceutical manufacturers in attendance, showing how digital and intelligent technologies can unlock sustainable growth for pharmaceutical companies and how DIGAI 2.0 can lead the industry along a new path of transformation.

PART.1

Building on Proven Capabilities and Deepening Expertise in Pharmaceutical Digitalization

As an expert in big data technology and solutions for the pharmaceutical and healthcare industry, Weiming Penguin has always pursued its mission of “Connecting Health.” It brings together seasoned experts from the internet and pharmaceutical sectors and draws on years of technology and management experience at Tencent. The company holds seven patents, including an intelligent data-matching algorithm for pharmaceutical distribution data cleansing (CN112685392A), as well as 49 national software copyrights covering industry databases, cleansing systems, analytics systems, and more. It has been recognized as a National High-Tech Enterprise for six consecutive years and is also a Zhongguancun High-Tech Enterprise, a Specialized, Refined, Distinctive, and Innovative Enterprise, and a Golden Seed Enterprise. Today, its team numbers 100 people working across Beijing, Dalian, Shanghai, and Chengdu. It has served nearly 100 domestic and foreign-invested healthcare companies, establishing a solid brand presence and professional reputation in the industry.

PART.
2

An Industry Leader's Perspective: Three Key Dimensions of Sustainable Growth for Pharmaceutical Companies

In the presentation, Tian Ying noted that, viewed from the perspective of industry leaders, pharmaceutical companies need to focus on three key dimensions to achieve sustainable growth:

1. Market expansion and revenue growth: This includes extending product lines, expanding channels into lower-tier markets and increasing their capacity, developing winning strategies for centralized procurement tenders, and expanding into international markets, opening up broader opportunities for growth.

2. Coordinating cost reduction and efficiency improvement: This includes building flexible production systems, implementing tiered customer management, controlling costs across the entire value chain, and developing a digital operations middle platform to achieve the best balance between cost and efficiency.

3. Resource reuse and collaboration: Shared R&D platforms, shared production capacity, and efforts to capture brand premiums maximize the value of resources and strengthen synergies.

Tian Ying further explained that these individual factors can be divided into those requiring sustained effort and those producing isolated bursts of growth. The ongoing factors can be distilled into three key terms: “commercialized products,” “commercialization partners,” and “partner value.” These three elements interact to support a company's long-term growth.

PART.
3

The Secrets to Success: Two Core Drivers of Digitally Enabled Growth

Based on a deep understanding of the industry, Tian Ying revealed the secrets to sustainable growth for pharmaceutical companies:

1. The golden sales formula: Continuously manage the three elements of “commercialized products,” “commercialization partners,” and “partner value,” using granular operations management to achieve steady growth in sales performance.

2. Break down digital silos: Provide efficient data-computing capabilities and eliminate data barriers so that data can flow freely throughout business operations and deliver its full value.

PART.4

DIGAI 2.0: AI + Big Data Enable Pharmaceutical Companies' Digital and Intelligent Transformation

Tian Ying highlighted Weiming Penguin's DIGAI Pharmaceutical Marketing Digitalization and Intelligence Solution 2.0. With its innovative three-in-one architecture of “Data–Insight–Growth,” the solution helps pharmaceutical companies achieve end-to-end digital transformation. Its original AI + BI intelligent analytics system effectively improves the accuracy of outlet coverage rates, and its collaboration with an anonymized pharmaceutical holding company has been selected as an “Annual Digital Transformation Benchmark.” A solid data foundation provided by the marketing middle platform, combined with productivity tools and AI tools, frees business teams from unnecessary burdens so they can focus on business development.

PART.
5

A Promising Future: Case Studies of AI Innovation at Pharmaceutical Companies

Tian Ying also shared three closed-door practical case studies: “Marketing Digitalization Case Study,” “AI Knowledge Base Lifecycle Management,” and “AI Best Practices for Pharmaceutical Manufacturers.” Through evidence-based analysis, these cases illustrated how pharmaceutical digitalization is evolving from an efficiency tool into a strategic core, offering the industry a replicable methodology for transformation.

1. Pharmaceutical companies still face three key challenges in applying AI: understanding, use cases, and security. In terms of understanding, misconceptions include the beliefs that AI can do everything, is useless, will replace people, or that more advanced models are inherently better. There is an urgent need to align employees around an accurate understanding of AI. In practical implementation, a lack of reference cases, ideas without tools, tools that are difficult to coordinate, and neglect of the operational promotion of AI applications all limit AI's ability to improve business efficiency. On the security front, companies also face data security dilemmas: awareness without tools, or tools without oversight. At this pharmaceutical industry conference, Weiming Penguin and its strategic partner DingTalk presented jointly, providing pharmaceutical companies with in-depth perspectives on AI innovation in practice.

2. In response to these industry pain points, DingTalk proposed four principles for AI innovation in pharmaceutical companies.

First, be use-case driven. AI should deliver not merely tools, but tangible productivity. Implementation should be driven by the actual business needs of each functional department in a pharmaceutical company, helping the company improve efficiency with AI, advance technological innovation, and expand its business overseas.

Second, teach people how to fish. Classify pharmaceutical companies' different AI needs into tiers and focus on building a system that enables them to operate AI independently. Establishing an AI capability center can help pharmaceutical companies coordinate knowledge management, improve their understanding of AI innovation, lower barriers to AI adoption, and accelerate the realization of AI-driven efficiency gains.

Third, inspire creativity. High-value AI applications must come from high-value use cases. By engaging and unleashing frontline employees' creativity, DingTalk builds widespread AI capabilities and an AI application mindset through AI boot camps, a DingTalk AI business efficiency roadmap, AI competitions, and other initiatives.

Fourth, put people first. Focus on the everyday work of pharmaceutical industry professionals so that employees can concentrate on “communication and innovation,” fully exercise their initiative, and combine it with AI technology to maximize work effectiveness.

3. Drawing on its extensive expertise in AI technology and innovative thinking, DingTalk has joined forces with Weiming Penguin to provide strong technical support for Weiming Penguin's pharmaceutical digitalization solutions. Together, they help pharmaceutical companies overcome difficulties in applying AI and achieve digital transformation and upgrades, bringing new energy to innovation in the pharmaceutical industry. They look forward to working with the industry to create more best practices and drive continued progress.

With its extensive expertise and innovative capabilities in AI-powered pharmaceutical digitalization, Weiming Penguin is becoming an important force in promoting sustainable growth for pharmaceutical companies. Tian Ying's presentation outlined a clear blueprint for digital transformation in the pharmaceutical and healthcare industry. Through continued investment in technology and operations, Weiming Penguin will remain firmly at the industry's forefront, continuously bringing innovative energy to AI-powered digitalization in pharmaceuticals and healthcare and leading the industry toward a new horizon of digital development.

2025318